Vitreoretinal and Uveitis Specialist
Dilraj Grewal, MD specializes in the medical and surgical management of patients with complex Vitreoretinal pathology and Uveitis. He joined the Duke Eye Center in December 2016 following completion of his Vitreoretinal Surgery fellowship at Duke and Uveitis fellowship training at Moorfields Eye Hospital in London. Dr. Grewal is excited about treating patients with several of the new diagnostic and therapeutic modalities available as well as several others in the pipeline to better help patients with these potentially blinding diseases.
He has been the recipient of numerous prestigious awards including the Ronald G. Michels Foundation Fellowship Award, the Heed Ophthalmic Foundation Fellowship Award, Senior Achievement Award from the American Academy of Ophthalmology and Rhett Buckler and Senior Honor Awards from American Society of Retina Specialists.
Dr. Grewal has authored over 100 publications in peer-reviewed medical journals and over 150 presentations at national and international meetings. His research interests span clinical research activities in advanced ocular imaging and clinical trials for both Retina and Uveitis. He also serves as Director of Grading at the Duke Reading Center, a comprehensive image reading center that specializes in systematic analysis of ophthalmic images captured by many different modalities in multicenter clinical trials. In addition, he participates in national and international clinical trials in retina and uveitis.
Education and Training
- Armed Forces Medical College (India), M.B.B.S. 2004
- University of Miami, Leonard M. Miller School of Medicine, Ophthalmology Bascom Palmer Eye Institute
- Northwestern University, Feinberg School of Medicine, General Surgery
- Northwestern University, Feinberg School of Medicine, Ophthalmology
- Duke University School of Medicine, Duke Eye Center
- Moorfields Eye Hospital NHS Foundation Trust (United Kingdom), Ophthalmology
Selected Grants and Awards
- Automated OCT Technology Translation to Diagnose Traumatic Eye Injury
- Novartis DRC Brolucizumab post-marketing imaging project
- DE-109 LUMINA
- Regeneron DRC A Double Masked Randomized, Controlled Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema Regeneron VGFT-1009 - Extension